Special Issue "Cancer Vaccines and Immunotherapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 May 2011)
Prof. Dr. W. Martin Kast
Walter A. Richter Cancer Research Chair, Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology, Norris Comprehensive Cancer Center (NRT 7507), University of Southern California, 1450 Biggy Street, MC 9601, Los Angeles, CA90033, USA
Phone: +1 323 442 3870
Fax: +1 323 442 7760
Interests: design of HPV immunotherapeutics; developing new and effective therapies for cervical cancer; prostate cancer and melanoma
Prof. Dr. Maurizio Chiriva-Internati
Division of Hematology and Oncology, Texas Tech University Health Sciences Center, 3601 4th St STOP, 6591, Lubbock, TX 79430, USA
Phone: +1-806-743-3155.ext. 279
Interests: tumor immunology, developing therapeutic and preventive tumor vaccine; ovarian cancer, multiple myeloma, breast cancer, prostate cancer
Despite intense ongoing research, many cancers are still incurable. Tumor cells induce immune tolerance, which represents a major obstacle for the application of cancer immunotherapy. Therefore, a current challenge for the field of cancer immunotherapy is to develop new approaches capable of breaking tumor-induced tolerance and inducing the (re-)activation of spontaneous and/or vaccine-triggered anti-tumor immune responses.
The exciting news this year is that we are now experiencing that cancer immunotherapy is finally becoming part of FDA approved cancer therapies. Cancer immunotherapy may provide a more effective and safer alternative approach to standard treatments, since unlike these currently available standard treatments, vaccines exploit natural anti-tumor immune surveillance, and offer the potential to provide durable control of primary and metastatic cancers.
Therefore, we invite research and review manuscripts in the field of cancer vaccines/cancer immunotherapy and topics related to new tumor antigen discovery, novel developments in therapeutic and preventive cancer vaccines, T regulatory cells, dendritic cell vaccines, T cell vaccines, B cell vaccines, pharmacological therapy, gene therapy, tumor-associated cancer testis antigens, immunosuppressive mechanisms, immune-regulatory applications and the regulation of immune surveillance against cancer as well as multi modality cancer approaches in which cancer vaccines/cancer immunotherapies play a role.
We are looking forward to your vital contributions.
Dr. W. Martin Kast
Dr. Maurizio Chiriva Internati
- cytotoxic T lymphocytes
- dendritic cells
- therapeutic cancer vaccines
- preventive cancer vaccines
- cancer immunotherapy